Analysts predict that ContraFect Corp (NASDAQ:CFRX) will report earnings per share (EPS) of ($0.09) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for ContraFect’s earnings, with estimates ranging from ($0.10) to ($0.08). ContraFect posted earnings of ($0.10) per share in the same quarter last year, which suggests a positive year over year growth rate of 10%. The business is expected to announce its next quarterly earnings results on Thursday, November 14th.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
On average, analysts expect that ContraFect will report full year earnings of ($0.12) per share for the current financial year, with EPS estimates ranging from ($0.17) to ($0.03). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.39) per share, with EPS estimates ranging from ($0.53) to ($0.25). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover ContraFect.
ContraFect (NASDAQ:CFRX) last announced its quarterly earnings results on Friday, August 9th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.09).
Several research analysts have weighed in on CFRX shares. Maxim Group reiterated a “buy” rating and issued a $2.00 price target on shares of ContraFect in a research report on Friday, October 4th. ValuEngine upgraded shares of ContraFect from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CFRX. Hartwell J M Limited Partnership raised its position in ContraFect by 40.0% in the second quarter. Hartwell J M Limited Partnership now owns 140,000 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 40,000 shares during the period. Trellus Management Company LLC bought a new position in ContraFect in the second quarter worth approximately $295,000. SG Americas Securities LLC bought a new position in ContraFect in the second quarter worth approximately $343,000. Finally, Oracle Investment Management Inc. raised its position in ContraFect by 13.1% in the second quarter. Oracle Investment Management Inc. now owns 6,356,649 shares of the biotechnology company’s stock worth $3,242,000 after acquiring an additional 735,450 shares during the period. Institutional investors and hedge funds own 34.94% of the company’s stock.
Shares of NASDAQ CFRX opened at $0.31 on Wednesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 4.15 and a current ratio of 4.15. ContraFect has a fifty-two week low of $0.27 and a fifty-two week high of $2.63. The stock has a market cap of $26.03 million, a price-to-earnings ratio of -0.84 and a beta of 0.17. The firm’s 50-day simple moving average is $0.34 and its 200 day simple moving average is $0.42.
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Recommended Story: Does the Dogs of the Dow strategy work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com